TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33992607
Drug: Sacubitril/valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (target dose of 400 mg daily)
Study: 33992607
Drug: Enalapril (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (target dose of 40 mg daily)
Study: 35085831
Drug: Treatment T
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment T
Study: 35085831
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment R
Study: 34793640
Drug: Combination paracetamol
Normalized name: paracetamol, combinations excl. psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination paracetamol iv (1 g) and ibuprofen iv (800 mg)
Study: 34793640
Drug: Paracetamol iv
Normalized name: PARACETAMOL IVAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol iv only (1 g)
Study: 34793640
Drug: Ibuprofen iv
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen iv only (800 mg)
Study: 34793640
Drug: Combination paracetamol
Normalized name: paracetamol, combinations excl. psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination paracetamol iv and ibuprofen iv
Study: 34793640
Drug: Paracetamol iv
Normalized name: PARACETAMOL IVAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol iv only
Study: 34793640
Drug: Ibuprofen iv
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen iv only
Study: 32440977
Drug: Dexamethasone 0.1%
Normalized name: DEXAMETHASONE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1% ophthalmic suspension
Study: 32440977
Drug: Bromfenac 0.09%
Normalized name: Bromfenac 0.09% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 0.09% ophthalmic solution
Study: 35555888
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral FeSO4 (150-200 mg) for 8 weeks
Study: 33871211
Drug: Weekly 300
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 300 mg azathioprine (n = 40)
Study: 33871211
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methotrexate every week (n = 40)
Study: 33400433
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections from two planes (Group C)
Study: 33400433
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections in one plane (Group E)
Study: 32964512
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (0.12% chlorhexidine gluconate + 3% sodium bicarbonate + nystatin 5000 U/mL)
Study: 32198861
Drug: Phenytoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (20 mg/kg over 20 minutes)
Study: 32198861
Drug: Valproate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (20 mg/kg over 20 minutes)
Study: 32198861
Drug: Levetiracetam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (20 mg/kg over 20 minutes)
Study: 32342846
Drug: Mass testing
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass testing and treatment (MTaT) of malaria infections, tested three times per year for two years, treated with dihydroartemisinin-piperaquine.
Study: 32342846
Drug: Mass testing
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass testing and treatment (MTaT) of malaria infections.
Study: 36068131
Drug: Vocal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal therapy with TENS (12 sessions of 20 min, pulse: 200μs, frequency: 10Hz) followed by vocal exercises (30 min)
Study: 36068131
Drug: Vocal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal therapy with TENS followed by vocal exercises
Study: 36068131
Drug: Vocal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal therapy without TENS
Study: 34190197
Drug: TXA, systemic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA, systemic, repeated 1 g bolus
Study: 34190197
Drug: TXA, topically
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA, topically intra-articularly, 2 g in 50 mL saline
Study: 36472034
Drug: Z‐VAD‐FMK (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z‐VAD‐FMK (20 μmol·L(‐1))
Study: 33200488
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nanocurcumin daily for 12 weeks
Study: 34658706
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of microneedling and chemical peeling (MN + CP)
Study: 33887209
Drug: Low-dose (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (1.3 µg) plus AF03
Study: 33887209
Drug: Low-dose (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (1.3 µg) plus AS03
Study: 33887209
Drug: High-dose (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (2.6 µg) plus AF03
Study: 33887209
Drug: High-dose (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (2.6 µg) plus AS03
Study: 33887209
Drug: Unadjuvanted high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted high-dose (2.6 µg)
Study: 33651033
Drug: Ultrasonic bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic bath with a special detergent solution (Group C)
Study: 34137526
Drug: Empagliflozin 10mg
Normalized name: EMPAGLIFLOZIN 10MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg twice a day
Study: 33598865
Drug: Anti-TNF-α treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α treatments
Study: 32690472
Drug: DHA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA treatment (2,152 mg of DHA per day)
Study: 34470656
Drug: DICA Br
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: DICA Br supplemented with 30 g/day of mixed nuts (10 g of peanuts, 10 g of cashew, 10 g of Brazil nuts)
Study: 33181580
Drug: Terbutaline (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (5-15 mg)
Study: 33181580
Drug: Imipramine (30-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (30-150 mg)
Study: 34687483
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine solution
Study: 35096742
Drug: Nomogram for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram for cancer-specific survival (CSS) based on independent prognostic factors (age, race, T stage, histological grade, surgery, radiotherapy, chemotherapy)
Study: 32045673
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg with 9 g charcoal (charcoal-block condition)
Study: 32045673
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 μg without charcoal (non-block condition)
Study: 32708971
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy with r-tPA (bolus, partial dose, or full dose)
Study: 32708971
Drug: Full r-tPA
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full r-tPA dose
Study: 36363493
Drug: Continuous cold
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cold flow (CCF) therapy
Study: 36363493
Drug: Cold pack
Normalized name: CVS Cold Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold pack (gel ice)
Study: 34116715
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 therapy
Study: 32446164
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) treatment including levetiracetam (LEV), valproic acid (VA), and carbamazepine.
Study: 33899292
Drug: delta-tocotrienol (δT3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta-tocotrienol (δT3) supplementation 250 mg once daily for 24 weeks
Study: 33899292
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose soft gel capsule)
Study: 33381204
Drug: Manipulative acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative acupuncture (acupoints acupuncture combined with manipulations of twirling, lifting, and thrusting treatments)
Study: 33381204
Drug: Simple acupuncture
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple acupuncture (acupoints acupuncture therapy alone)
Study: 35672832
Drug: E-HELD intervention
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-HELD intervention (therapist-guided Internet-based cognitive-behavioral therapy)
Study: 32152326
Drug: T1 (2.5 g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1 (2.5 g/L foliar application twice at nursery with a one‐week interval)
Study: 35798020
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g prunes
Study: 33739437
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (12 weeks, twice weekly)
Study: 33479274
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered in the first 48 hours after birth
Study: 33479274
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics administered in the first 48 hours after birth
Study: 32006180
Drug: Engagement in
Normalized name: Bispecific t-cell engager antibody regn4018
DrugBank: Ubamatamab (DB18875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engagement in discussions on disease experiences, medications, social lives, online resources on RA, frustrations, messages of encouragement, and satirical depictions of their disease experience.
Study: 35567778
Drug: Early autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy
Study: 34390604
Drug: Enriched RS2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched RS2 cookies (16 g d-1 of Hi-Maize 260, Ingredion) for 4 weeks
Study: 34178124
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg intramuscular neridronate given once daily for 16 consecutive days
Study: 33246494
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT), 30–40 treatment sessions in a high pressure chamber (2.4 atmospheres absolute) inhaling 100% oxygen through a mask.
Study: 32043986
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg IV once daily from day 1 to day 5, then 10 mg IV once daily from day 6 to day 10)
Study: 33971353
Drug: Brolucizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab (3 or 6 mg)
Study: 33971353
Drug: Brolucizumab therapy
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab therapy continued after first IOI-related AE
Study: 33971353
Drug: Brolucizumab therapy
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab therapy not continued after first IOI-related AE
Study: 33971353
Drug: Brolucizumab injections
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab injections before first IOI-related AE
Study: 35325834
Drug: Low crude
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low crude fiber diet (30 g/kg CF)
Study: 34484379
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of hydrocortisone (50 mg/6 h, intravenously), Vitamin C (1.5 g/6 h in 100 ml normal saline or DW5%, intravenously), and thiamine (200 mg/12 h in 50 ml normal saline or DW5%, intravenously)
Study: 34484379
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of hydrocortisone, thiamine, and Vitamin C
Study: 33303119
Drug: TMVr plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMVr plus guideline-directed medical therapy (GDMT)
Study: 36335573
Drug: benzoate 1000
Normalized name: benzoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzoate 1000 (500 mg/day for the first 4 weeks, 1000 mg/day from the 5th week)
Study: 36335573
Drug: benzoate 500
Normalized name: aminobenzoate 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzoate 500 (fixed 500 mg/day)
Study: 36335573
Drug: benzoate 750
Normalized name: imidazole-2-hydroxybenzoate 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzoate 750 (500 mg/day for the first 4 weeks, 750 mg/day from the 5th week)
Study: 32556619
Drug: Patient-specific titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific titanium onlay implant
Study: 32317617
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with Reduced Calcineurin Inhibitor Exposure
Study: 34971525
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg i.v. infusion over 40 min)
Study: 34971525
Drug: Ketamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (10 mg/kg i.p.)
Study: 34971525
Drug: (2R,6R)‐HNK (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2R,6R)‐HNK (10 mg/kg i.p.)
Study: 33063096
Drug: Nurse-led self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led self-management and self-assessment program including educational video and home-based exercises, with monthly reporting of ASDAS/BASDAI scores.
Study: 32073608
Drug: Low-calorie breakfast
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie breakfast (11% of daily kilocalorie requirement)
Study: 32073608
Drug: High-calorie dinner
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie dinner (69% of daily kilocalorie requirement)
Study: 34406315
Drug: 5.25% NaOCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% NaOCI solution
Study: 34406315
Drug: 5.25% NaOCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% NaOCI gel
Study: 32419594
Drug: 8-mg intramuscular
Normalized name: ISOtretinoin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg intramuscular injections of a non-viral DNA plasmid
Study: 32419594
Drug: 16-mg intramuscular
Normalized name: afamelanotide 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-mg intramuscular injections of a non-viral DNA plasmid
Study: 35751777
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) solid formulation, 200 mcg orally administered at 08:00 h
Study: 35751777
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) liquid formulation, 200 mcg orally administered at 08:00 h
Study: 32659160
Drug: Simulated Treatment
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated Treatment Comparison (STC)
Study: 33890449
Drug: Costoclavicular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costoclavicular block (CC)
Study: 35761262
Drug: L‐HIIT (supervised)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐HIIT (supervised)
Study: 33085801
Drug: Tailored pharmacist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored pharmacist-led intervention based on adherence barriers (forgetfulness, lack of knowledge, lack of motivation, other drug-related problems)
Study: 34705785
Drug: Patient-specific implants
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific implants
Study: 33346683
Drug: Colchicine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (25 nmol/L)
Study: 35476143
Drug: Galcanezumab 300
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 300 mg subcutaneously every 4 weeks
Study: 35025542
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy (IPT)
Study: 33852248
Drug: Oral sarecycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sarecycline (once-daily, weight-based dosing)
Study: 33852248
Drug: Control (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (multivitamin tablet)
Study: 32852531
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg, weeks 1 and 3)
Study: 32852531
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus Ipilimumab (Ipilimumab 1 mg/kg, week 1 only)
Study: 35685982
Drug: Allograft patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allograft patch augmentation
Study: 35685982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CC subgroup)
Study: 35685982
Drug: Allograft group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allograft group (CC subgroup)
Study: 36213912
Drug: Fear-focused Self-compassion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fear-focused Self-compassion Therapy
Study: 34818379
Drug: Voriconazole treatment
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole treatment
Study: 32951999
Drug: Sublingual sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sufentanil tablet system
Study: 32951999
Drug: Nurse-controlled continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-controlled continuous morphine infusion
Study: 32886131
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatment (Control)
Study: 36286675
Drug: Remaxol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol (400 ml/day)
Study: 36286675
Drug: Heptral (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptral (800 mg/day)
Study: 32915426
Drug: Dingkun Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dingkun Pill (7 g daily for 21 days, followed by 7 drug-free days)
Study: 32915426
Drug: Diane‐35 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane‐35 (1 tablet daily for 21 days, followed by 7 drug-free days)
Study: 32915426
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (Dingkun Pill and Diane‐35)
Study: 35005040
Drug: Meaning-centered play
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meaning-centered play intervention, implemented in twelve 45-minute sessions, twice a week for six weeks.
Study: 32646743
Drug: Deferral of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferral of statin therapy
Study: 33236676
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy problems (adverse drug reactions)
Study: 32898792
Drug: Switch maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch maintenance chemotherapy (pemetrexed 500 mg/m2 d1, 22 for non-squamous cell carcinoma; gemcitabine 1,150 mg/m2 d1, 8, 22 for squamous cell carcinoma)
Study: 32898792
Drug: Switch maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch maintenance chemotherapy
Study: 35953245
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin two times per day
Study: 35060404
Drug: Single-session Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session Acceptance and Commitment Therapy intervention (<3 hours)
Study: 32554365
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of 20 mL 0.5% bupivacaine HCl (100 mg) after implantation
Study: 32554365
Drug: Combined periarticular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined periarticular injection of 20 mL 0.5% bupivacaine HCl (100 mg) and incisional injection of 10 mL 0.5% bupivacaine HCl (50 mg)
Study: 35285906
Drug: 1.50 g
Normalized name: Dimethicone 1.50 g in 150 mL TOPICAL EMULSION [VITAMIN B5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.50 g · kg‐1 · d‐1 protein plus multinutrient beverage (NUT)
Study: 35285906
Drug: 0.900 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.900 g · kg‐1 · d‐1 protein plus placebo (PLA)
Study: 33381794
Drug: Glucose supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose supplementation 3 times daily
Study: 33381794
Drug: Fructose supplementation
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose supplementation 3 times daily
Study: 33203954
Drug: ASP4345 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP4345 (3, 15, 50, and 150 mg; n = 9 each dose)
Study: 33317824
Drug: Sunlight treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunlight treatment
Study: 33935152
Drug: Digital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital therapy group (12-week home-based digitally assisted rehabilitation program with 13 face-to-face sessions)
Study: 33935152
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (30 sessions of conventional face-to-face physical therapy)
Study: 32181830
Drug: Nonaerosol spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonaerosol spray sunscreen
Study: 35586820
Drug: Warming Yang,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming Yang, tonifying kidney, and removing arthralgia therapy
Study: 35586820
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment not specified)